Steven Cohen Autolus Therapeutics PLC Transaction History
Point72 Asset Management, L.P.
- $40.1 Billion
- Q1 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 34,645 shares of AUTL stock, worth $83,148. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,645
Previous 247,089
85.98%
Holding current value
$83,148
Previous $580,000
90.86%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding AUTL
# of Institutions
99Shares Held
163MCall Options Held
0Put Options Held
88.3K-
Wellington Management Group LLP Boston, MA27.1MShares$65 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$49.2 Million0.14% of portfolio
-
Deep Track Capital, LP Greenwich, CT17.8MShares$42.8 Million0.97% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$39.9 Million97.79% of portfolio
-
Armistice Capital, LLC New York, NY11MShares$26.4 Million0.26% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $218M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...